The results revealed that RRM2 expression was significantly increased in most cancer groups, including bladder, brain, breast, cervical, colorectal, esophageal, gastric, head and neck, kidney, liver, lung, lymphoma, melanoma, ovarian, pancreatic, prostate, and sarcoma cancers. The gene discussed is RRM2; the disease is melanoma.